Transcutaneously tunneled central venous lines in cancer patients

An analysis of device-related morbidity factors based on prospective data collection

Roderich E. Schwarz, Daniel G. Coit, Jeffrey S. Groeger

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Long-term transcutaneous tunneled central venous catheters are frequently placed in cancer patients, accounting for significant costs and morbidity. Factors influencing outcome, though, are poorly studied. Methods: Between June 1991 and June 1993, 923 central venous tunneled catheters were placed in 791 patients at Memorial Sloan-Kettering Cancer Center. Placement-, device-, and patient-related parameters were charted prospectively (median follow-up: 120 days) and correlated to device-specific outcome events. Results: Median patient age was 28.5 years (range: 0.025 - 84.5). Disease distribution included hematologic malignancies (64.7%), solid tumors (30.4%), and others (4.9%). Primary indications for line access included chemotherapy (72.8%), bone marrow transplantation (18.7%), total parenteral nutrition (6.4%), and drug administration (2.1%). There were 11 insertion complications (1.2%), including insertion failure (n = 6), hemorrhage (n = 4), and malposition (n = 1). Subsequent to placement, a proven or suspected device specific complication occurred in 540 lines (58.5%). Per 10,000 catheter days, there were 17.6 infection episodes, 8.1 thrombotic complications, 6.9 instances of catheter breakage, 3.5 accidental or inadvertent cases of displacement, and 0.6 device leaks. Reasons for line removal or other termination of follow-up were patient's death (32.1%), treatment end (28%), infection (19.6%), suspected infection (6.3%), displacement (6.8%), thrombosis (3.1%), leak (1%), and others (3.1%). Median device-specific duration was 365 days, compared with a median complication- free device-specific duration of 167 days (P < 0.0001), reflecting a highly significant device salvage rate after complications. Catheter tip position emerged as the dominant independent prognostic factor for reduced device- specific duration or complication-free device-specific duration. Conclusions: Transcutaneous tunneled central venous lines can be placed safely, with a considerable incidence of subsequent device-specific complications, but a high salvage rate. Factors determining outcome are related to device placement, as well as the patient's disease status. In this study, patients alive 90 days after catheter placement had a 37% chance for a device complication, with a 20% chance for device loss. Future analyses of intermediate-term intravenous access should employ the measurement of device- specific outcome as a reference parameter to assess clinical results.

Original languageEnglish (US)
Pages (from-to)441-449
Number of pages9
JournalAnnals of Surgical Oncology
Volume7
Issue number6
StatePublished - Jul 2000

Fingerprint

Morbidity
Equipment and Supplies
Neoplasms
Catheters
Central Venous Catheters
Infection
Total Parenteral Nutrition
Hematologic Neoplasms
Bone Marrow Transplantation
Thrombosis
Hemorrhage
Costs and Cost Analysis
Drug Therapy
Incidence
Pharmaceutical Preparations

Keywords

  • Cancer
  • Catheter-related complications
  • Device-specific outcome
  • Intravenous access

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Transcutaneously tunneled central venous lines in cancer patients : An analysis of device-related morbidity factors based on prospective data collection. / Schwarz, Roderich E.; Coit, Daniel G.; Groeger, Jeffrey S.

In: Annals of Surgical Oncology, Vol. 7, No. 6, 07.2000, p. 441-449.

Research output: Contribution to journalArticle

@article{1109bd737ab243fd9a0030fb621b4984,
title = "Transcutaneously tunneled central venous lines in cancer patients: An analysis of device-related morbidity factors based on prospective data collection",
abstract = "Background: Long-term transcutaneous tunneled central venous catheters are frequently placed in cancer patients, accounting for significant costs and morbidity. Factors influencing outcome, though, are poorly studied. Methods: Between June 1991 and June 1993, 923 central venous tunneled catheters were placed in 791 patients at Memorial Sloan-Kettering Cancer Center. Placement-, device-, and patient-related parameters were charted prospectively (median follow-up: 120 days) and correlated to device-specific outcome events. Results: Median patient age was 28.5 years (range: 0.025 - 84.5). Disease distribution included hematologic malignancies (64.7{\%}), solid tumors (30.4{\%}), and others (4.9{\%}). Primary indications for line access included chemotherapy (72.8{\%}), bone marrow transplantation (18.7{\%}), total parenteral nutrition (6.4{\%}), and drug administration (2.1{\%}). There were 11 insertion complications (1.2{\%}), including insertion failure (n = 6), hemorrhage (n = 4), and malposition (n = 1). Subsequent to placement, a proven or suspected device specific complication occurred in 540 lines (58.5{\%}). Per 10,000 catheter days, there were 17.6 infection episodes, 8.1 thrombotic complications, 6.9 instances of catheter breakage, 3.5 accidental or inadvertent cases of displacement, and 0.6 device leaks. Reasons for line removal or other termination of follow-up were patient's death (32.1{\%}), treatment end (28{\%}), infection (19.6{\%}), suspected infection (6.3{\%}), displacement (6.8{\%}), thrombosis (3.1{\%}), leak (1{\%}), and others (3.1{\%}). Median device-specific duration was 365 days, compared with a median complication- free device-specific duration of 167 days (P < 0.0001), reflecting a highly significant device salvage rate after complications. Catheter tip position emerged as the dominant independent prognostic factor for reduced device- specific duration or complication-free device-specific duration. Conclusions: Transcutaneous tunneled central venous lines can be placed safely, with a considerable incidence of subsequent device-specific complications, but a high salvage rate. Factors determining outcome are related to device placement, as well as the patient's disease status. In this study, patients alive 90 days after catheter placement had a 37{\%} chance for a device complication, with a 20{\%} chance for device loss. Future analyses of intermediate-term intravenous access should employ the measurement of device- specific outcome as a reference parameter to assess clinical results.",
keywords = "Cancer, Catheter-related complications, Device-specific outcome, Intravenous access",
author = "Schwarz, {Roderich E.} and Coit, {Daniel G.} and Groeger, {Jeffrey S.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "7",
pages = "441--449",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Transcutaneously tunneled central venous lines in cancer patients

T2 - An analysis of device-related morbidity factors based on prospective data collection

AU - Schwarz, Roderich E.

AU - Coit, Daniel G.

AU - Groeger, Jeffrey S.

PY - 2000/7

Y1 - 2000/7

N2 - Background: Long-term transcutaneous tunneled central venous catheters are frequently placed in cancer patients, accounting for significant costs and morbidity. Factors influencing outcome, though, are poorly studied. Methods: Between June 1991 and June 1993, 923 central venous tunneled catheters were placed in 791 patients at Memorial Sloan-Kettering Cancer Center. Placement-, device-, and patient-related parameters were charted prospectively (median follow-up: 120 days) and correlated to device-specific outcome events. Results: Median patient age was 28.5 years (range: 0.025 - 84.5). Disease distribution included hematologic malignancies (64.7%), solid tumors (30.4%), and others (4.9%). Primary indications for line access included chemotherapy (72.8%), bone marrow transplantation (18.7%), total parenteral nutrition (6.4%), and drug administration (2.1%). There were 11 insertion complications (1.2%), including insertion failure (n = 6), hemorrhage (n = 4), and malposition (n = 1). Subsequent to placement, a proven or suspected device specific complication occurred in 540 lines (58.5%). Per 10,000 catheter days, there were 17.6 infection episodes, 8.1 thrombotic complications, 6.9 instances of catheter breakage, 3.5 accidental or inadvertent cases of displacement, and 0.6 device leaks. Reasons for line removal or other termination of follow-up were patient's death (32.1%), treatment end (28%), infection (19.6%), suspected infection (6.3%), displacement (6.8%), thrombosis (3.1%), leak (1%), and others (3.1%). Median device-specific duration was 365 days, compared with a median complication- free device-specific duration of 167 days (P < 0.0001), reflecting a highly significant device salvage rate after complications. Catheter tip position emerged as the dominant independent prognostic factor for reduced device- specific duration or complication-free device-specific duration. Conclusions: Transcutaneous tunneled central venous lines can be placed safely, with a considerable incidence of subsequent device-specific complications, but a high salvage rate. Factors determining outcome are related to device placement, as well as the patient's disease status. In this study, patients alive 90 days after catheter placement had a 37% chance for a device complication, with a 20% chance for device loss. Future analyses of intermediate-term intravenous access should employ the measurement of device- specific outcome as a reference parameter to assess clinical results.

AB - Background: Long-term transcutaneous tunneled central venous catheters are frequently placed in cancer patients, accounting for significant costs and morbidity. Factors influencing outcome, though, are poorly studied. Methods: Between June 1991 and June 1993, 923 central venous tunneled catheters were placed in 791 patients at Memorial Sloan-Kettering Cancer Center. Placement-, device-, and patient-related parameters were charted prospectively (median follow-up: 120 days) and correlated to device-specific outcome events. Results: Median patient age was 28.5 years (range: 0.025 - 84.5). Disease distribution included hematologic malignancies (64.7%), solid tumors (30.4%), and others (4.9%). Primary indications for line access included chemotherapy (72.8%), bone marrow transplantation (18.7%), total parenteral nutrition (6.4%), and drug administration (2.1%). There were 11 insertion complications (1.2%), including insertion failure (n = 6), hemorrhage (n = 4), and malposition (n = 1). Subsequent to placement, a proven or suspected device specific complication occurred in 540 lines (58.5%). Per 10,000 catheter days, there were 17.6 infection episodes, 8.1 thrombotic complications, 6.9 instances of catheter breakage, 3.5 accidental or inadvertent cases of displacement, and 0.6 device leaks. Reasons for line removal or other termination of follow-up were patient's death (32.1%), treatment end (28%), infection (19.6%), suspected infection (6.3%), displacement (6.8%), thrombosis (3.1%), leak (1%), and others (3.1%). Median device-specific duration was 365 days, compared with a median complication- free device-specific duration of 167 days (P < 0.0001), reflecting a highly significant device salvage rate after complications. Catheter tip position emerged as the dominant independent prognostic factor for reduced device- specific duration or complication-free device-specific duration. Conclusions: Transcutaneous tunneled central venous lines can be placed safely, with a considerable incidence of subsequent device-specific complications, but a high salvage rate. Factors determining outcome are related to device placement, as well as the patient's disease status. In this study, patients alive 90 days after catheter placement had a 37% chance for a device complication, with a 20% chance for device loss. Future analyses of intermediate-term intravenous access should employ the measurement of device- specific outcome as a reference parameter to assess clinical results.

KW - Cancer

KW - Catheter-related complications

KW - Device-specific outcome

KW - Intravenous access

UR - http://www.scopus.com/inward/record.url?scp=0033948522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033948522&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 441

EP - 449

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -